MET inhibitors for MET amplification—What’s the most appropriate detection method and cut-off value?

MET amplification, one type of MET genomic alteration, plays an important role in tumor development and epidermal growth factor receptor tyrosine–kinase inhibitor (EGFR‑TKI) resistance. Various clinical trials of MET-targeted therapy stratified by the degree of MET amplification have been conducted in multiple cancers. Strikingly, some clinical studies have indicated that a correlation between the efficacy of MET inhibitors and the level of MET amplification. However, inconsistent of MET amplification criteria and detection methods in different clinical trials, confound amplification detection and targeted treatment [1–3].